738 related articles for article (PubMed ID: 31666296)
41. Evolutionary Rationale for Phages as Complements of Antibiotics.
Torres-Barceló C; Hochberg ME
Trends Microbiol; 2016 Apr; 24(4):249-256. PubMed ID: 26786863
[TBL] [Abstract][Full Text] [Related]
42. Phage therapy administered noninvasively could be effective in thin tubes subject to episodic flow despite washout: a simulation study.
Blanco C; Chen IA
Phys Biol; 2019 Jul; 16(5):054001. PubMed ID: 31266001
[TBL] [Abstract][Full Text] [Related]
43. Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections.
Abedon ST
Adv Drug Deliv Rev; 2019 May; 145():18-39. PubMed ID: 31708017
[TBL] [Abstract][Full Text] [Related]
44. Making the leap from technique to treatment - genetic engineering is paving the way for more efficient phage therapy.
Lewis JM; Williams J; Sagona AP
Biochem Soc Trans; 2024 Jun; 52(3):1373-1384. PubMed ID: 38716972
[TBL] [Abstract][Full Text] [Related]
45. Understanding and Exploiting Phage-Host Interactions.
Stone E; Campbell K; Grant I; McAuliffe O
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216787
[TBL] [Abstract][Full Text] [Related]
46. Biological foundations of successful bacteriophage therapy.
Venturini C; Petrovic Fabijan A; Fajardo Lubian A; Barbirz S; Iredell J
EMBO Mol Med; 2022 Jul; 14(7):e12435. PubMed ID: 35620963
[TBL] [Abstract][Full Text] [Related]
47. Bacteriophage-mediated modulation of microbiota for diseases treatment.
Zhang Y; Li CX; Zhang XZ
Adv Drug Deliv Rev; 2021 Sep; 176():113856. PubMed ID: 34237403
[TBL] [Abstract][Full Text] [Related]
48. Phage therapy for severe bacterial infections: a narrative review.
Petrovic Fabijan A; Khalid A; Maddocks S; Ho J; Gilbey T; Sandaradura I; Lin RC; Ben Zakour N; Venturini C; Bowring B; Iredell JR
Med J Aust; 2020 Apr; 212(6):279-285. PubMed ID: 31587298
[TBL] [Abstract][Full Text] [Related]
49. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.
Łobocka M; Dąbrowska K; Górski A
BioDrugs; 2021 May; 35(3):255-280. PubMed ID: 33881767
[TBL] [Abstract][Full Text] [Related]
50. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts.
Royer S; Morais AP; da Fonseca Batistão DW
Arch Microbiol; 2021 May; 203(4):1271-1279. PubMed ID: 33474609
[TBL] [Abstract][Full Text] [Related]
51. Steering Phages to Combat Bacterial Pathogens.
Gurney J; Brown SP; Kaltz O; Hochberg ME
Trends Microbiol; 2020 Feb; 28(2):85-94. PubMed ID: 31744662
[TBL] [Abstract][Full Text] [Related]
52. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review.
Kakasis A; Panitsa G
Int J Antimicrob Agents; 2019 Jan; 53(1):16-21. PubMed ID: 30236954
[TBL] [Abstract][Full Text] [Related]
53. Virulence-associated factors as targets for phage infection.
de Melo AG; Morency C; Moineau S
Curr Opin Microbiol; 2024 Jun; 79():102471. PubMed ID: 38569419
[TBL] [Abstract][Full Text] [Related]
54. The disparate effects of bacteriophages on antibiotic-resistant bacteria.
Torres-Barceló C
Emerg Microbes Infect; 2018 Oct; 7(1):168. PubMed ID: 30302018
[TBL] [Abstract][Full Text] [Related]
55. The relationship between the phageome and human health: are bacteriophages beneficial or harmful microbes?
Fernández L; Duarte AC; Rodríguez A; García P
Benef Microbes; 2021 Apr; 12(2):107-120. PubMed ID: 33789552
[TBL] [Abstract][Full Text] [Related]
56. Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.
Rohde C; Resch G; Pirnay JP; Blasdel BG; Debarbieux L; Gelman D; Górski A; Hazan R; Huys I; Kakabadze E; Łobocka M; Maestri A; Almeida GMF; Makalatia K; Malik DJ; Mašlaňová I; Merabishvili M; Pantucek R; Rose T; Štveráková D; Van Raemdonck H; Verbeken G; Chanishvili N
Viruses; 2018 Apr; 10(4):. PubMed ID: 29621199
[TBL] [Abstract][Full Text] [Related]
57. Bacteriophage Adherence to Mucus Mediates Preventive Protection against Pathogenic Bacteria.
Almeida GMF; Laanto E; Ashrafi R; Sundberg LR
mBio; 2019 Nov; 10(6):. PubMed ID: 31744913
[TBL] [Abstract][Full Text] [Related]
58. Bacteriophage therapy for management of bacterial infections in veterinary practice: what was once old is new again.
Squires RA
N Z Vet J; 2018 Sep; 66(5):229-235. PubMed ID: 29925297
[TBL] [Abstract][Full Text] [Related]
59. Reapproaching Old Treatments: Considerations for PK/PD Studies on Phage Therapy for Bacterial Respiratory Infections.
Schmalstig AA; Freidy S; Hanafin PO; Braunstein M; Rao GG
Clin Pharmacol Ther; 2021 Jun; 109(6):1443-1456. PubMed ID: 33615463
[TBL] [Abstract][Full Text] [Related]
60. Flagellotropic Bacteriophages: Opportunities and Challenges for Antimicrobial Applications.
Esteves NC; Scharf BE
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
